QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10.26

CONFIDENTIAL TREATMENT REQUEST
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN
SEPARATELY FILED WITH THE COMMISSION

NINTH AMENDMENT TO
MANUFACTURING & DISTRIBUTION AGEEMENT

        This NINTH AMENDMENT, dated as of November 25, 2002, amends that certain
Manufacturing & Distribution Agreement by and between GENSIA SICOR
PHARMACEUTICAL SALES, INC. ("Gensia Sicor") (assignee of Gensia Sicor
Pharmaceuticals, Inc., formerly Gensia Laboratories, Ltd.) and BAXTER HEALTHCARE
CORPORATION ("Baxter") (formerly Ohmeda Pharmaceutical Products Division Inc.)
dated as of February 27, 1996, as amended (the "Agreement").

        1.    Section 2.4 of the Agreement is amended to add the following new
Section 2.4.2 immediately following the end thereof:

        "2.4.2    Sales and Inventory Reports.    Baxter shall provide Gensia
Sicor with sales reports for each product within ten (10) days of the end of
each calendar quarter during the term of this Agreement, and inventory reports
for each product within ten (10) days of the end of each month during the term
of this Agreement, in the format in which it is currently provided."

        2.    A new Section 2.7.3 is added to the Agreement as follows:

        "2.7.3    Alternative Formulations of Injectable
Propofol.    Notwithstanding anything in this Agreement to the contrary, in the
event either Baxter or Gensia Sicor desires to develop, acquire or license, or
is offered an opportunity to develop, acquire, or license a product, technology,
process, or other intellectual property rights in a formulation of injectable
propofol other than the formulation currently being marketed by Baxter under
this Agreement or other formulations currently manufactured by or for either
Baxter or Gensia Sicor in any other area of the world as of the date of this
Ninth Amendment, irrespective of whether such formulation can be marketed under
an ANDA, an NDA, or an application pursuant to section 505(b)(2) of the Food,
Drug and Cosmetic Act (a "New Propofol Formulation"), such party shall promptly
notify the other party in writing. In the event such party wishes to pursue the
opportunity, it shall offer the other party the right ***. Prior to
commercialization, the parties shall mutually agree on the allocation of costs
for the manufacture, marketing, sales and distribution of the New Propofol
Formulation. In the event such other party elects not to accept the right set
forth herein, such other party shall nonetheless be entitled to receive a ***.
In the event such party does not wish to pursue the opportunity, the other party
shall be free to do so, provided that the first party shall be entitled to
receive a ***. Notwithstanding the foregoing, with respect to formulations of
propofol for veterinary use, the provisions of this section shall be subject to
the rights and obligations of the parties under agreements existing at the time
this amendment is executed."

***    Confidential Treatment has been requested with respect to certain
portions of this agreement.

        3.    Section 2.10 of the Agreement (including subsections 2.10.1
through 2.10.5, inclusive) is deleted in its entirety and replaced with the
following:

        "2.10    Baxter Purchase Obligations.    Baxter agrees to purchase the
following Gensia Sicor products in finished dosage form sufficient to meet all
of Baxter's needs for such products in the Territory: atropine, bumetanide,
diltiazem, enalaprilat, hetastarch, neostigmine, nitroprusside and
phenylephrine."

        4.    Sections 2.12 and 2.12.1 of the Agreement are deleted in their
entirety and replaced with the following:

        "2.12    Option to Discontinue Products.    In the event Gensia Sicor
deems it commercially unreasonable for it to continue to sell any Product
presentation to Baxter hereunder for reasons due to financial hardship, raw
material or component availability, Gensia Sicor shall have the right

--------------------------------------------------------------------------------

(at its option, in its sole discretion) to terminate this Agreement as to such
Product presentation by written notice to Baxter. If Gensia Sicor elects to
terminate this Agreement as to any such Product presentation, then Baxter shall
have the right, which may be exercised only by written notice to Gensia Sicor
within thirty (30) days after Baxter's receipt of the termination notice from
Gensia Sicor, to continue this Agreement as to such Product presentation for a
period (the "Continuation Period") of up to one (1) year after the date of
Gensia Sicor's receipt of the continuation notice from Baxter; provided,
however, that during the Continuation Period with respect to any such Product
presentation, Gensia Sicor shall not be obligated to deliver to Baxter more than
the quantity of such Product presentation ordered in good faith by Baxter as
necessary to satisfy its requirements under those contracts of Baxter existing
and in effect as of the date of Baxter's receipt of the termination notice under
this Section 2.12.

        In the event Baxter deems it commercially unreasonable for it to
continue to purchase any Product presentation from Gensia Sicor hereunder for
reasons due to financial hardship, raw material or component availability,
Baxter shall have the right (at its option, in its sole discretion) to terminate
this Agreement as to such Product presentation by written notice to Gensia
Sicor. If Baxter elects to terminate this Agreement as to any such Product
presentation, then Gensia Sicor shall have the right, which may be exercised
only by written notice to Baxter within thirty (30) days after Gensia Sicor's
receipt of the termination notice from Baxter, to continue this Agreement as to
such Product presentation for a period (the "Continuation Period") of up to one
(1) year after the date of Baxter's receipt of the continuation notice from
Gensia Sicor; provided, however, that during the Continuation Period with
respect to any such Product presentation, Baxter shall not be obligated to
purchase from Gensia Sicor more than the quantity of such Product presentation
required pursuant to section 2.13.4."

        5.    Section 2.13.4 of the Agreement is amended to add at the end
thereof the following:

"From and after January 1, 2003, Baxter agrees to purchase from Gensia Sicor
during each calendar year at least the number of finished dosage units of
Propofol equivalent to *** of compounded one percent (1%) bulk propofol.
Notwithstanding the foregoing, Baxter's annual minimum purchase obligation
pursuant to the preceding sentence shall (x) terminate in the event that another
generic form of propofol is launched by a third party, or (y) be reduced by ***
upon the launch of Diprivan® 2% propofol or another propofol product approved
under an NDA. Subject to the following sentence, in the event Baxter fails to
meet such minimum purchase obligations during any calendar year then it will pay
Gensia Sicor an amount equal to the purchase price (as calculated under the
Agreement) of the number liters of Propofol by which its applicable minimum
annual purchase requirement exceeds the number of liters actually purchased.
Notwithstanding the preceding sentence, in the event Baxter fails to purchase
from Gensia Sicor during each calendar year at least the number of finished
dosage units of Propofol equivalent to *** of compounded bulk propofol, Gensia
Sicor shall have the right to terminate this Agreement as to Propofol, provided
that Baxter shall have a period of six (6) months in which to cure such failure
by purchasing the amount of the prior year's shortfall. If, at the end of such
six (6) month period, Baxter has not purchased at least the number of finished
dosage units of Propofol equivalent to the sum of such shortfall plus *** of
compounded bulk propofol, Gensia Sicor shall have the right to terminate this
Agreement immediately. If for any reason not caused by an act or omission of
Baxter Gensia Sicor cannot supply Propofol to Baxter for more than 45 days,
Baxter's applicable minimum annual purchase requirement will be reduced on a pro
rata basis."

***    Confidential Treatment has been requested with respect to certain
portions of this agreement.

        6.    A new section 2.14 is added to the Agreement as follows:

        "2.14    Business Review.    Responsible representatives of Baxter and
Gensia Sicor shall meet in person on a quarterly basis to review Product
performance."

2

--------------------------------------------------------------------------------

        7.    Section 5.1 of the Agreement is deleted in its entirety and
replaced with the following:

        "5.1    Transfer Price.    Effective January 1, 2003, the price for each
Product presentation ("Transfer Price"), other than Hetastarch and Propofol, to
be delivered to Baxter by Gensia Sicor during the term of this Agreement shall
be *** as set forth in Exhibit C hereto. Baxter shall pay to Gensia Sicor an
amount equal to ***. For Propofol, the Transfer Price shall be ***. For
Hetastarch, the purchase price shall be as described in section 5.5. The terms
of payment are net thirty (30) days from date of invoice which invoice shall not
predate the shipment of Products."

***    Confidential Treatment has been requested with respect to certain
portions of this agreement.

        8.    Section 5.2 of the Agreement is deleted in its entirety and
replaced with the following:

        "5.2    Adjustments to Transfer Price.    Except with respect to
Hetastarch, the Transfer Prices set forth in Exhibit C will be adjusted at the
beginning of each Annual Period to reflect ***. The Transfer Price for
Hetastarch shall be adjusted pursuant to the terms of section 5.5. Gensia Sicor
shall provide written notice of such adjustment thirty (30) days prior to the
date of the adjustment."

***    Confidential Treatment has been requested with respect to certain
portions of this agreement.

        9.    Section 5.3 of the Agreement is amended to add a new section 5.3.3
as follows:

        "5.3.3    Limitation.    In no event shall any Percentage Payment made
under this section 5.3 be less than ***."

***    Confidential Treatment has been requested with respect to certain
portions of this agreement.

        10.  Section 6.1 of the Agreement is amended to strike the phrase "nine
(9)" and insert the phrase "thirteen (13)", and to add to the last sentence
thereof the phrase, "provided that such notice may not be given before
December 31, 2006".

        11.  Promptly following execution of this Ninth Amendment, Baxter shall
grant to Gensia Sicor the exclusive right in the United States to manufacture,
market and sell milrinone under Baxter's current ANDA filed with the FDA. As of
the Effective Date of this Amendment, Gensia Sicor shall release Baxter from its
obligation to purchase all of its requirements for milrinone from Gensia Sicor.

        12.  Except as specifically set forth above, all other terms and
conditions set forth in the Agreement shall remain unchanged.

        13.  Capitalized terms not otherwise defined herein shall have the
meaning ascribed to them in the Agreement.

3

--------------------------------------------------------------------------------

        IN WITNESS WHEREOF the parties hereto have executed this Amendment as of
the date first above written.

GENSIA SICOR PHARMACEUTICAL SALES, INC.   BAXTER HEALTHCARE CORPORATION
By:
 
    

--------------------------------------------------------------------------------

 
By:
    

--------------------------------------------------------------------------------

Name:
 
    

--------------------------------------------------------------------------------

 
Name:
    

--------------------------------------------------------------------------------

Title:
 
    

--------------------------------------------------------------------------------

 
Title:
    

--------------------------------------------------------------------------------

GENSIA SICOR PHARMACEUTICALS, INC.
 
 
 
By:
 
    

--------------------------------------------------------------------------------

 
 
 
Name:
 
    

--------------------------------------------------------------------------------

 
 
 
Title:
 
    

--------------------------------------------------------------------------------

 
 
 

4

--------------------------------------------------------------------------------

QuickLinks

Exhibit 10.26

NINTH AMENDMENT TO MANUFACTURING & DISTRIBUTION AGEEMENT